Progress of neoadjuvant chemotherapy for pancreatic cancer
10.3760/cma.j.issn.1673-4203.2009.05.017
- VernacularTitle:胰腺癌新辅助化疗进展
- Author:
Peng GONG
;
Zhongyu WANG
- Publication Type:Journal Article
- Keywords:
pancreatic cancer;
neoadjuvant chemotherapy
- From:
International Journal of Surgery
2009;36(5):335-338
- CountryChina
- Language:Chinese
-
Abstract:
Surgical treatment has improved the prognosis of resectable pancreatic cancer considerably de-spite the generally aggressive behavior of its malignancy. Neoadjuvant therapy for pancreatic cancer has been shown effective in improving a survival benefit. Few prospective randomized controlled clinical trials (RCTs) on the use of neoadjuvant chemotherapy and chemoradiation has been done tp show the survival advantage of systemic chemotherapy (5-FU/FA or gemcitabine) following surgical resection. Up to now, there is no high-level evidence of any benefit deriving from neoadjuvant chemo therapy for pancreatic cancer. Well designed trials are needed to compare neoadjuvant chemotherapy with surgery to judge the value of neoadjuvant cherqo-therapy in multimodal treatment concepts of pancreatic cancer.
